Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

HIV-EnvHIV-Env gene DNA recombinant envelope protein antigen immune response experiment and method for resisting HIV

An envelope protein and antigen immunization technology, applied in the field of life sciences, can solve the problems of inability to trigger the human immune tolerance mechanism, loss of specific amino acid structural epitopes, etc.

Inactive Publication Date: 2008-07-02
叶新新
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The inventor believes that: 1. Change one or some amino acid structures of HIV envelope protein gp120 or gp160—the heterogeneous specific ligand antigen molecule of human CD4 receptor, so that it loses the specific amino acid structure binding to human CD4 receptor epitope, cannot bind to the human CD4 receptor; it will not trigger human immune tolerance mechanisms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] In order to achieve the above objectives, the scheme adopted in the implementation of the present invention:

[0010] HIV-Env gene DNA Allosteric Recombinant envelope protein antigen immune response anti-HIV experiment and method

[0011] 1. Laboratory animals and humans in clinical trials

[0012] 1.1. Experimental animals: 4-6 weeks old sterile animals, CBA / Ca mice, C57BL / 6 mice or BALB / c mice, Hu-PBL-SCID mice; non-human primates, Ganges Monkey, gorilla.

[0013] 1.2. Humans in clinical trials: normal healthy people who are not infected with HIV-I, and patients infected with HIV-I in the acute phase.

[0014] 2. Experimental biological materials

[0015] 2.1. Use rat anti-mouse CD4 receptor monoclonal antibody IgG2a / b-mouse CD4 receptor heterogeneous specific ligand antigen to simulate HIV envelope protein gp120 or gp160-human CD4 receptor heterogeneous specific ligand Somatic antigen; rat anti-human or anti-rabbit monoclonal antibody IgG2a / b-a heterogeneous antigen that...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an anti-HIV immune response apparatus of an HIV-Env DNA recombinant envelope protein antigen and a method thereof, belonging to life science and medicinal fields. The clinic experiment in human body prove that vaccines derived from HIV envelope protein gp120 or gp160 can not prevent HIV infection, because the HIV envelope protein gp120 or gp160 is a heterogeneous specific ligand that can specifically bind with CD4<+> cells-specific receptor CD4<+> receptor and induce immunological tolerance mechanism of human body but can not inducing immune response mechanism for effectively eliminating HIV. The invention can be used for searching a method for solving immunological tolerance mechanism of human body, developing an anti-HIV vaccine derived from HIV-Env DNA recombinant envelope protein antigen for preventing and treating HIV that does not induce immunological tolerance mechanism of human body, and providing sufficient scientific reference for direct animal model experiments and direct clinical human trials.

Description

Technical field [0001] The invention relates to an HIV-Env gene DNA allosteric recombinant envelope protein antigen immune response anti-HIV experiment and method. It involves the field of life sciences, and the field of medicine. It can reveal the human replication of HIV infection, through the envelope protein gp120-the heterogeneous specific ligand antigen of human CD4 receptor, and human CD4 + The specific binding of cell-specific receptors triggers the immune tolerance mechanism of HIV-infected persons. It has a highly variable immune escape mechanism than HIV, and is more effective against the body's immune suppression pressure. Confirmation: The clinical human trials of all different HIV envelope protein gp160 and gp120 antigen vaccines designed and developed by HIV vaccine scientific research can not prove that it can prevent HIV from infecting humans. The most important factor is: HIV envelope protein gp120 Or gp160 is a heterogeneous specific ligand antigen of human CD4 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/53G01N33/577C07K16/18C07K14/16
Inventor 叶新新
Owner 叶新新
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com